Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
Background. Transarterial chemoembolization (TACE) is the most common treatment for patients with HCC who are unsuitable for radical therapies. Conventional TACE (cTACE) takes advantage of the preferential hepatic arterial supply of HCC for the targeted delivery of chemotherapeutic agents suspended...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Applied Bionics and Biomechanics |
| Online Access: | http://dx.doi.org/10.1155/2022/9084852 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402893884456960 |
|---|---|
| author | Man Yao Simo Cheng Xiaofeng Zhai Hetong Zhao Jing Hong Xiaoyan Li Yongbin Meng Wei Chen |
| author_facet | Man Yao Simo Cheng Xiaofeng Zhai Hetong Zhao Jing Hong Xiaoyan Li Yongbin Meng Wei Chen |
| author_sort | Man Yao |
| collection | DOAJ |
| description | Background. Transarterial chemoembolization (TACE) is the most common treatment for patients with HCC who are unsuitable for radical therapies. Conventional TACE (cTACE) takes advantage of the preferential hepatic arterial supply of HCC for the targeted delivery of chemotherapeutic agents suspended in lipiodol, followed by embolization or reduction of arterial flow using various types of particles while sparing the surrounding liver parenchyma. Aims and Objectives. The current study is aimed at comparing the efficacy and safety profiles of transarterial infusion of recombinant human type-5 adenovirus (H101-TACE) with conventional transarterial chemoembolization (cTACE) in patients with unresectable hepatocellular carcinoma (HCC). Methods. Unresectable HCC patients that received H101-based TACE or cTACE from August 2018 to September 2021 were retrospectively evaluated. Propensity score matching (PSM) has a 1 : 1 ratio to eliminate possible confounder imbalances across cohorts. The main outcome was overall survival (OS), while secondary outcomes were progression-free survival (PFS) and tumor response. Results. This study included 111 patients classified across two cohorts: the H101-TACE cohort (n=37) and the cTACE cohort (n=74). Median OS within the H101-TACE cohort was 9.0 months longer than within the cTACE cohort before PSM (22.1 vs. 13.1 months, P=0.043) and 9.3 months longer following PSM (22.1 vs. 12.8 months, P=0.004). The median PFS within the H101-TACE cohort was 3.2 months longer compared to the cTACE cohort before PSM (6.5 vs. 3.3 months, P=0.046) and 2.5 months after PSM (6.5 vs. 4.0 months, P=0.012). The disease control rate for H101 and control cohorts was 81.1% and 59.5%, accordingly (P=0.039). Conclusion. The present study demonstrated that the H101-TACE is safe and efficient and can considerably enhance prognostic results for unresectable HCC compared to cTACE. |
| format | Article |
| id | doaj-art-94500b6e4f5e400d84ee13e99cdc35d0 |
| institution | Kabale University |
| issn | 1754-2103 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Applied Bionics and Biomechanics |
| spelling | doaj-art-94500b6e4f5e400d84ee13e99cdc35d02025-08-20T03:37:24ZengWileyApplied Bionics and Biomechanics1754-21032022-01-01202210.1155/2022/9084852Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching AnalysisMan Yao0Simo Cheng1Xiaofeng Zhai2Hetong Zhao3Jing Hong4Xiaoyan Li5Yongbin Meng6Wei Chen7Department of Integrative OncologySchool of Traditional Chinese MedicineDepartment of Integrative OncologySchool of Traditional Chinese MedicineDepartment of RadiologyDepartment of Integrative OncologyDepartment of Integrative OncologyDepartment of RadiologyBackground. Transarterial chemoembolization (TACE) is the most common treatment for patients with HCC who are unsuitable for radical therapies. Conventional TACE (cTACE) takes advantage of the preferential hepatic arterial supply of HCC for the targeted delivery of chemotherapeutic agents suspended in lipiodol, followed by embolization or reduction of arterial flow using various types of particles while sparing the surrounding liver parenchyma. Aims and Objectives. The current study is aimed at comparing the efficacy and safety profiles of transarterial infusion of recombinant human type-5 adenovirus (H101-TACE) with conventional transarterial chemoembolization (cTACE) in patients with unresectable hepatocellular carcinoma (HCC). Methods. Unresectable HCC patients that received H101-based TACE or cTACE from August 2018 to September 2021 were retrospectively evaluated. Propensity score matching (PSM) has a 1 : 1 ratio to eliminate possible confounder imbalances across cohorts. The main outcome was overall survival (OS), while secondary outcomes were progression-free survival (PFS) and tumor response. Results. This study included 111 patients classified across two cohorts: the H101-TACE cohort (n=37) and the cTACE cohort (n=74). Median OS within the H101-TACE cohort was 9.0 months longer than within the cTACE cohort before PSM (22.1 vs. 13.1 months, P=0.043) and 9.3 months longer following PSM (22.1 vs. 12.8 months, P=0.004). The median PFS within the H101-TACE cohort was 3.2 months longer compared to the cTACE cohort before PSM (6.5 vs. 3.3 months, P=0.046) and 2.5 months after PSM (6.5 vs. 4.0 months, P=0.012). The disease control rate for H101 and control cohorts was 81.1% and 59.5%, accordingly (P=0.039). Conclusion. The present study demonstrated that the H101-TACE is safe and efficient and can considerably enhance prognostic results for unresectable HCC compared to cTACE.http://dx.doi.org/10.1155/2022/9084852 |
| spellingShingle | Man Yao Simo Cheng Xiaofeng Zhai Hetong Zhao Jing Hong Xiaoyan Li Yongbin Meng Wei Chen Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis Applied Bionics and Biomechanics |
| title | Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis |
| title_full | Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis |
| title_fullStr | Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis |
| title_full_unstemmed | Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis |
| title_short | Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis |
| title_sort | prognostic comparison between ctace and h101 tace in unresectable hepatocellular carcinoma hcc a propensity score matching analysis |
| url | http://dx.doi.org/10.1155/2022/9084852 |
| work_keys_str_mv | AT manyao prognosticcomparisonbetweenctaceandh101taceinunresectablehepatocellularcarcinomahccapropensityscorematchinganalysis AT simocheng prognosticcomparisonbetweenctaceandh101taceinunresectablehepatocellularcarcinomahccapropensityscorematchinganalysis AT xiaofengzhai prognosticcomparisonbetweenctaceandh101taceinunresectablehepatocellularcarcinomahccapropensityscorematchinganalysis AT hetongzhao prognosticcomparisonbetweenctaceandh101taceinunresectablehepatocellularcarcinomahccapropensityscorematchinganalysis AT jinghong prognosticcomparisonbetweenctaceandh101taceinunresectablehepatocellularcarcinomahccapropensityscorematchinganalysis AT xiaoyanli prognosticcomparisonbetweenctaceandh101taceinunresectablehepatocellularcarcinomahccapropensityscorematchinganalysis AT yongbinmeng prognosticcomparisonbetweenctaceandh101taceinunresectablehepatocellularcarcinomahccapropensityscorematchinganalysis AT weichen prognosticcomparisonbetweenctaceandh101taceinunresectablehepatocellularcarcinomahccapropensityscorematchinganalysis |